Search results for " alpha 2"

showing 5 items of 5 documents

Acute Phase Proteins Are Baseline Predictors of Tuberculosis Treatment Failure

2021

Systemic inflammation is a characteristic feature of pulmonary tuberculosis (PTB). Whether systemic inflammation is associated with treatment failure in PTB is not known. Participants, who were newly diagnosed, sputum smear and culture positive individuals with drug-sensitive PTB, were treated with standard anti-tuberculosis treatment and classified as having treatment failure or microbiological cure. The plasma levels of acute phase proteins were assessed at baseline (pre-treatment). Baseline levels of C-reactive protein (CRP), alpha-2 macroglobulin (a2M), Haptoglobin and serum amyloid P (SAP) were significantly higher in treatment failure compared to cured individuals. ROC curve analysis …

AdultMalemedicine.medical_specialtyTuberculosisImmunologyAntitubercular AgentsSystemic inflammationGastroenterologyCohort StudiesInternal medicinemedicineHumansImmunology and AllergyProspective StudiesTreatment FailureTuberculosis PulmonaryOriginal ResearchHaptoglobinsbiologybusiness.industryHaptoglobinAcute-phase proteinArea under the curveRC581-607Middle Agedmedicine.diseasePregnancy-Associated alpha 2-MacroglobulinsMacroglobulinSerum Amyloid P-ComponentC-Reactive ProteintuberculosisROC CurveinflammationTB treatmentacute phase proteinsbiology.proteinbiomarkerSputumBiomarker (medicine)FemaleImmunologic diseases. Allergymedicine.symptombusinessBiomarkersAcute-Phase ProteinsFrontiers in Immunology
researchProduct

MO945SERUM AND URINE LEUCINE RICH ALPHA-2-GLYCOPROTEIN-1 IS ASSOCIATED WITH KIDNEY TRANSPLANT INJURY AND FAILURE

2021

Abstract Background and Aims Kidney transplantation is the treatment of choice for most of the patients with end stage chronic kidney disease. To improve patient and graft survival, early diagnostics and discovery of specific biomarkers is important. Leucine rich alpha-2-glycoprotein-1 (LRG-1) is an innovative, non-invasive biomarker that is elevated in case of angiogenesis, inflammation and kidney injury. Aim was to evaluate biomarker LRG-1 level in serum and urine in kidney transplant recipients in accordance with kidney injury markers and time period after kidney transplantation. Method In the study 35 patients were enrolled. Patients had functioning kidney grafts and they were more than…

Transplantationmedicine.medical_specialtyProteinuriabusiness.industryUrineKidney transplantEndocrinologyNephrologyInternal medicinemedicinePrednisoloneGraft survivalLeucine rich alpha 2 glycoproteinmedicine.symptombusinessmedicine.drugNephrology Dialysis Transplantation
researchProduct

Secondary reduction in calpain 3 expression in patients with limb girdle muscular dystrophy type 2B and Miyoshi myopathy (primary dysferlinopathies).

2000

Made available in DSpace on 2016-10-10T03:52:18Z (GMT). No. of bitstreams: 5 Secondary reduction in calpain 3 expression in patients with limb girdle muscular dystrophy type 2B and Miyoshi myopathy.pdf: 167085 bytes, checksum: b445ec059ea2d0f06bd4fa913354872a (MD5) license_url: 52 bytes, checksum: 2f32edb9c19a57e928372a33fd08dba5 (MD5) license_text: 24259 bytes, checksum: f1f24f769b03eb8f9cd3f53c1090841c (MD5) license_rdf: 24658 bytes, checksum: 9d3847733d3c0b59c7c89a1d40d3d240 (MD5) license.txt: 1887 bytes, checksum: 445d1980f282ec865917de35a4c622f6 (MD5) Previous issue date: 2000 Dysferlin is the protein product of the gene (DYSF) that is defective in patients with limb girdle muscular dy…

medicine.medical_specialtyDysferlinopathyDNA Mutational AnalysisMuscle ProteinsMuscular DystrophiesWestern blottingDysferlinMuscular DiseasesLamininInternal medicinemedicineMissense mutationCalpain 3HumansMuscular dystrophyDysferlinGenetics (clinical)Geneticsbiologybusiness.industryCalpainMembrane ProteinsCalpainmedicine.diseaseMuscular dystrophyLaminin alpha 2EndocrinologyMuscle proteinsNeurologyPediatrics Perinatology and Child Healthbiology.proteinNeurology (clinical)LamininbusinessMerosinLimb-girdle muscular dystrophyNeuromuscular disorders : NMD
researchProduct

Vinblastine and interferon-alpha-2a regimen in the treatment of metastatic renal cell carcinoma.

1990

Thirteen patients with histologically proven advanced and/or metastatic renal cell carcinoma (RCC) were treated with vinblastine (Velbe, Eli Lilly, Sesto Fiorentino, Italy) and interferon-alpha-2a (Roferon-A, Roche, Milan). Eleven out of 13 patients were evaluable. Eighteen percent of patients had partial response, 46 % stable disease (SD), and 36 % progressive disease (PD). The mean survival of responders was 228+ days, whereas the patients showing SD and PD had a mean survival of 154+ and 107+ days respectively. Toxicity, including influenza-like syndrome, fever, neurological and gastrointestinal side effects, was generally mild. However, medication with paracetamol was required in 82 % …

OncologyAdultMaleCancer Researchmedicine.medical_specialtyInterferon alpha-2VinblastineGastroenterology03 medical and health sciences0302 clinical medicineStable DiseaseRenal cell carcinomaPartial responseInternal medicinemedicineHumans030212 general & internal medicineInterferon Alpha 2aCarcinoma Renal CellAgedbusiness.industryInterferon-alphaGeneral MedicineMiddle Agedmedicine.diseaseKidney NeoplasmsRecombinant ProteinsVinblastineRegimenOncology030220 oncology & carcinogenesisToxicityInterferon Type IDrug Therapy CombinationFemalebusinessProgressive diseasemedicine.drugTumori
researchProduct

Long-term follow-up and novel genotype-phenotype analysis of monozygotic twins with ATP1A3 mutation in Alternating Hemiplegia of Childhood-2

2020

Alternating Hemiplegia of Childhood (AHC) is a rare disorder characterized by frequent, transient attacks of hemiplegia involving either side of the body or both in association to several other disturbances including dystonic spells, abnormal ocular movements, autonomic manifestations, epileptic seizures and cognitive impairment. The clinical manifestations usually start before the age of 18 months. Two forms of the disorder known as AHC-1 (MIM#104290) and AHC-2 (MIM#614820) depends on mutations in ATP1A2 and ATP1A3 genes respectively, with over 75% of AHC caused by a mutation in the ATP1A3 gene. Herewith, we report serial clinical follow-up data of monozygotic (MZ) twin sisters, who presen…

Pediatricsmedicine.medical_specialtyGenotype-phenotype correlationGenotypeTwinsHemiplegiaMonozygoticEpilepsyYoung AdultSettore MED/38 - Pediatria Generale E SpecialisticaATP1A2Alternating Hemiplegia of Childhood (AHC)ATP1A3GenotypeGeneticsmedicineHumansYoung adultATPase Na+/K+ transporting subunit alpha 2 (ATP1A2)Genetics (clinical)DystoniaATPase Na+/K+ transporting subunit alpha 3 (ATP1A3)business.industryAlternating hemiplegia of childhoodp.Asn773SerGeneral MedicineTwins Monozygoticmedicine.diseasePhenotypePhenotypeMutationFemaleSodium-Potassium-Exchanging ATPasebusiness
researchProduct